SOX2 expression in the developing, adult, as well as, diseased prostate

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 4, 2014, Pages 301-309

  Yu, X ^a   Cates, J M ^a   Morrissey, C ^b   You, C ^a   Grabowska, M M ^a   Zhang, J ^a   Degraff, D J ^a   Strand, D W ^a   Franco, O E ^a   Lin Tsai, O ^a   Hayward, S W ^a   Matusik, R J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SYNAPTOPHYSIN; TRANSCRIPTION FACTOR SOX2; SOX2 PROTEIN, HUMAN; SOX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SOX;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; EPITHELIUM BASAL CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; MORPHOGENESIS; MOUSE; NONHUMAN; ORGANOGENESIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE DEVELOPMENT; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; EMBRYOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROENDOCRINE TUMOR; PROSTATE; PROSTATE TUMOR; TISSUE MICROARRAY; TRANSGENIC MOUSE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SOXB1 TRANSCRIPTION FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84909982232     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.29     Document Type: Article

References (38)

1. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000; 227: 239-255.
2. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3: 167-170.
3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
4. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol 2008; 317: 296-309.
5. Tompkins DH, Besnard V, Lange AW, Wert SE, Keiser AR, Smith AN et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One 2009; 4: e8248.
6. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010; 5: e11022.
7. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011; 71: 18-25.
8. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045-2053.
9. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011; 3: 230-238.
10. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One 2013; 8: e53701.
11. Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS One 2012; 7: e36326.
12. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012; 40: 6725-6740.
13. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012; 31: 2270-2282.
14. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011; 104: 1410-1417.
15. Girouard SD, Laga AC, Mihm MC, Scolyer RA, Thompson JF, Zhan Q et al. SOX2 contributes to melanoma cell invasion. Lab Invest 2012; 92: 362-370.
16. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W et al. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif 2012; 45: 207-216.
17. Laga AC, Lai CY, Zhan Q, Huang SJ, Velazquez EF, Yang Q et al. Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell biology. Am J Pathol 2010; 176: 903-913.
18. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010; 18: 55-61.
19. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71.
20. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006; 30: 705-712.
21. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-9216.
22. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013; 15: 1-10.
23. Grabowska MM, Degraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD et al. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev 2014 (in press).
24. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998; 78: 319-334.
25. Masumori N, Thomas TZ, Case T, Paul M, Kasper S, Chaurand P et al. A probasin-large T antigen transgenic mouse line develops prostate adeno and neuro-endocrine carcinoma with metastatic potential. Cancer Res 2001; 61: 2239-2249.
26. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172: 236-246.
27. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T et al. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 2004; 171: 439-442.
28. Yu X, Wang YQ, Jiang M, Bierie BB, Hayward SW, Shen MM et al. Activated beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 2009; 69: 249-262.
29. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011; 30: 1868-1879.
30. Mirosevich J, Gao N, Matusik RJ. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 2005; 62: 339-352.
31. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35: 403-409.
32. Dagvadorj A, Tan SH, Liao Z, Cavalli LR, Haddad BR, Nevalainen MT. Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin Cancer Res 2008; 14: 6062-6072.
33. Jiang M, Strand DW, Fernandez S, He Y, Yi Y, Birbach A et al. Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells. Stem Cells 2010; 28: 344-356.
34. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-e389.
35. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006; 66: 1013-1029.
36. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009; 40: 252-258.
37. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendo-crine tumor cells of human prostate cancer. Prostate 2009; 69: 787-798.
38. Sotomayor P, Godoy A, Smith GJ, Huss WJ. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69: 401-410.